-
公开(公告)号：EP3131896B1
公开(公告)日：2019-01-30
申请号：EP15779184.9
申请日：2015-04-10
发明人： SAKURADA, Isao , HIRABAYASHI, Tomokazu , MAEDA, Yoshitaka , NAGASUE, Hiroshi , MIZUNO, Takashi , XU, Jiayi , ZHANG, Ting , SMITH, Cameron , PARKER, Dann
IPC分类号： C07D413/14 , C07D261/20 , C07D207/02 , A61K31/439
-
公开(公告)号：EP3209667A1
公开(公告)日：2017-08-30
申请号：EP15853228.3
申请日：2015-10-21
发明人： YOUNG, Katherine , OLSEN, David B. , SINGH, Sheo B. , SU, Jing , WILKENING, Robert R. , APGAR, James M. , MENG, Dongfang , PARKER, Dann , MANDAL, Mihir , YANG, Lihu , PAINTER, Ronald E. , DANG, Qun , SUZUKI, Takao
IPC分类号： C07D493/10
CPC分类号： C07D493/08 , C07C53/18 , C07C309/06 , C07D493/18 , C07D519/00 , C07F7/1856
摘要： The present invention relates to novel nargenicin related compounds which can inhibit DnaE and have antibacterial, particularly antimycobacterial activity against Mycobacterium tuberculosis. The present invention also relates to method for inhibiting growth of mycobacterial cells as well as a method of treating mycobacterial infections by Mycobacterium tuberculosis by administering an antimycobacterially effective amount of nargenicin or a nargenicin-related compound and/or their pharmaceutically acceptable salts.
摘要翻译： 本发明涉及新的可以抑制DnaE并具有抗细菌特别是抗结核分枝杆菌的抗分枝杆菌活性的Nargenicin相关化合物。 本发明还涉及抑制分枝杆菌细胞生长的方法以及通过施用抗分枝杆菌有效量的Nargenicin或Narragein相关化合物和/或其药学上可接受的盐来治疗结核分枝杆菌的分枝杆菌感染的方法。
-
公开(公告)号：EP3131896A1
公开(公告)日：2017-02-22
申请号：EP15779184.9
申请日：2015-04-10
发明人： SAKURADA, Isao , HIRABAYASHI, Tomokazu , MAEDA, Yoshitaka , NAGASUE, Hiroshi , MIZUNO, Takashi , XU, Jiayi , ZHANG, Ting , SMITH, Cameron , PARKER, Dann
IPC分类号： C07D413/14 , C07D261/20 , C07D207/02
CPC分类号： A61K31/439 , A61K31/444 , A61K31/501 , A61K31/506 , A61K45/06 , C07D209/52 , C07D261/20 , C07D413/04 , C07D413/14 , C07D498/04 , C07D519/00
摘要： In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.
摘要翻译： 在其许多实施方案中，本发明提供了一类由式（I）表示的新型苯甲酰胺化合物或其药学上可接受的盐或溶剂合物，或包含一种或多种所述化合物或其药学上可接受的盐或溶剂化物的药物组合物，以及使用 所述化合物或其药学上可接受的盐或溶剂化物用于治疗或预防血栓形成，栓塞，高凝状态或纤维化改变。
-
公开(公告)号：EP3974413A1
公开(公告)日：2022-03-30
申请号：EP21202075.4
申请日：2014-12-17
发明人： HAGMANN, William K. , LI, Bing , SZEWCZYK, Jason, W. , WANG, Bowei , PARKER, Dann , BLIZZARD, Timothy , JOSIEN, Hubert , BIJU, Purakkattle , CHOBANIAN, Harry , GUDE, Candido , NARGUND, Ravi, P. , PIO, Barbara , DANG, Qun , LIN, Linus, S. , HU, Bin , CUI, Mingxiang , CHEN, Zhengxia , DAI, Meibi , ZHANG, Zaihong , LV, Ying , TIAN, Lili
IPC分类号： C07D213/64 , C07D213/74 , C07D221/20 , C07D239/34 , C07D401/04 , C07D401/12 , C07D405/12 , C07D409/12 , C07D417/04 , C07D451/06 , C07D471/04 , C07D493/04 , A61K31/437 , A61K31/438 , A61K31/44 , A61K31/443 , A61K31/4433 , A61K31/4436 , A61K31/4439 , A61K31/4545 , A61K31/505
摘要： The present invention relates to a compound represented by formula I:
and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.-
公开(公告)号：EP3131897A1
公开(公告)日：2017-02-22
申请号：EP15780578.9
申请日：2015-04-10
发明人： SAKURADA, Isao , HIRABAYASHI, Tomokazu , MAEDA, Yoshitaka , NAGASUE, Hiroshi , MIZUNO, Takashi , XU, Jiayi , ZHANG, Ting , SMITH, Cameron , PARKER, Dann
IPC分类号： C07D413/14 , C07D261/20 , C07D207/02
CPC分类号： C07D413/14 , A61K31/423 , A61K31/428 , A61K31/437 , A61K31/4439 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/52 , A61K45/06 , C07D413/04 , C07D417/14 , C07D471/04 , C07D498/04 , C07D519/00
摘要： In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.
摘要翻译： 在其许多实施方案中，本发明提供了由式（I）表示的新一类苯甲酰胺化合物或其药学上可接受的盐或溶剂合物，或包含一种或多种所述化合物或其药学上可接受的盐或溶剂合物的药物组合物，以及使用 所述化合物或其药学上可接受的盐或溶剂化物用于治疗或预防血栓形成，栓塞，高凝状态或纤维变性。
-
公开(公告)号：EP3122343A2
公开(公告)日：2017-02-01
申请号：EP15767840.0
申请日：2015-03-23
发明人： MITCHELL, Helen , FRALEY, Mark, E. , COOKE, Andrew, J. , STUMP, Craig, A. , ZHANG, Xu-Fang , MCCOMAS, Casey, C. , SCHIRRIPA, Kathy , MCWHERTER, Melody , LIU, Ping , PARKER, Dann , LI, Chun Sing , MAO, Qinghua
IPC分类号： A61K31/166
CPC分类号： C07D487/04 , C07D231/40 , C07D277/46 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/12 , C07D403/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/04
摘要： The present invention is directed to substituted five membered heteroaryl benzamide compounds of formula (I) (Formula (I)) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.
摘要翻译： 本发明涉及作为原肌球蛋白相关激酶（Trk）家族蛋白激酶抑制剂的式（I）（式（I））的取代的五元杂芳基苯甲酰胺化合物，因此可用于治疗疼痛，炎症，癌症 ，再狭窄，动脉粥样硬化，银屑病，血栓形成，与髓鞘形成障碍或神经生长因子（NGF）受体TrkA异常活性相关的疾病或病症有关的疾病，病症，损伤或功能障碍。
-
公开(公告)号：EP3082786A1
公开(公告)日：2016-10-26
申请号：EP14870903.3
申请日：2014-12-17
发明人： HAGMANN, William, K. , LI, Bing , SZEWCZYK, Jason, W. , WANG, Bowei , PARKER, Dann , BLIZZARD, Timothy , JOSIEN, Hubert , BIJU, Purakkattle , CHOBANIAN, Harry , GUDE, Candido , NARGUND, Ravi, P. , PIO, Barbara , DANG, Qun , LIN, Linus, S. , HU, Bin , CUI, Mingxiang , CHEN, Zhengxia , DAI, Meibi , ZHANG, Zaihong , LV, Ying , TIAN, Lili
IPC分类号： A61K31/192 , A61K31/381
CPC分类号： C07D493/04 , A61K31/437 , A61K31/438 , A61K31/44 , A61K31/443 , A61K31/4433 , A61K31/4436 , A61K31/4439 , A61K31/4545 , A61K31/46 , A61K31/505 , A61K31/506 , A61K45/06 , C07D213/64 , C07D213/74 , C07D221/20 , C07D239/34 , C07D401/04 , C07D401/12 , C07D405/12 , C07D409/12 , C07D417/04 , C07D451/06 , C07D471/04
摘要： The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.017 秒)
